Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cipatinib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Collaborators: Chinese Academy of Medical Sciences